Effectiveness of Covid-19 Vaccination on BA.4/BA.5 Variant: A Review of Current Literature

Main Article Content

Mahmood Dashti Nozhan i Azim Shohreh Ghasemi

Abstract

The B.1.1.529 (Omicron) variant of SARS-CoV-2 has rapidly spread with many variants like BA.1, BA.2, BA3., BA4., and BA5. With sublineages as well. It (Omicron) was first discovered in November 2021 and has become the predominant variant in several nations. Due to the sensitivity of infection and various other limitations like no particular real-time data for different age groups, there is a lack of information on the actual efficacy of vaccines against this variant. Limitations of data and reviews and the incidence of emergence rather than hospitalized people would result in an underestimation of the efficacy of vaccines against severe diseases. This systematic review was conducted by following PRISMA guidelines. Specific inclusion and exclusion parameters were strictly followed. Our studies show that a substantial number of people have received mRNA COVID-19 vaccine doses. The booster dose must be administered and obtained immediately before all efforts to stop the pandemic go to waste. Focusing on the primary vaccination is no longer sufficient.

Keywords: COVID-19 vaccines, Efficacy, Booster dose, Omicron variation

Article Details

How to Cite
DASHTI, Mahmood; AZIM, Nozhan i; GHASEMI, Shohreh. Effectiveness of Covid-19 Vaccination on BA.4/BA.5 Variant: A Review of Current Literature. Medical Research Archives, [S.l.], v. 11, n. 3, mar. 2023. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3583>. Date accessed: 20 apr. 2024. doi: https://doi.org/10.18103/mra.v11i3.3583.
Section
Review Articles

References

1. Qu P, Evans JP, Faraone J, et al. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2. Preprint. bioRxiv. 2022;2022.10.19.512891. Published 2022 Oct 20. doi:10.1101/2022.10.19.512891

2. Hachmann NP, Miller J, Collier AY, Ventura JD, Yu JY, Rowe M, et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. New England Journal of Medicine.
3. Mohapatra RK, Kandi V, Sarangi AK, Verma S, Tuli HS, Chakraborty S, Chakraborty C, Dhama K. The recently emerged BA. 4 and BA. 5 lineages of Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic–Correspondence. International Journal of Surgery (London, England). 2022 Jul;103:106698.
4. Chaki SP, Kahl-McDonagh MM, Neuman BW, Zuelke KA. Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants. Microbiology Spectrum. 2022 May 31:e00665-22
5. Qu P, Faraone JN, Evans JP, Zou X, Zheng YM, Carlin C, et al. Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. 2022.
6. Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
7. AIDS Institute and Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China.
8. Moosa Y, Mattison S, Gazy I, Fish M, Singh L, Khanyile KS, San JE, Fonseca V, Giovanetti M, Alcantara LC, de Oliveira T. 2020. Whole genome sequencing of SARS-CoV-2: adapting Illumina protocols for quick and accurate outbreak investigation during a pandemic.
9. John G, Sahajpal NS, Mondal AK, Ananth S, Williams C, Chaubey A, Rojiani AM, Kolhe R. 2021. Next-generation sequencing (NGS) in COVID-19: a tool for SARS-CoV-2 diagnosis, monitoring new strains and phylodynamic modeling in molecular epidemiology. Curr Issues Mol Biol 43:845–867.
10. Bezerra MF, Machado LC, De Carvalho V, Docena C, Brandao-Filho SP, Ayres CFJ, Paiva MHS, Wallau GL. 2021. A Sanger-based approach for scaling up screening of SARS-CoV-2 variants of interest and concern. Infect Genet Evol 92:104910.
11. Simonetti M, Zhang N, Harbers L, Milia MG, Brossa S, Huong Nguyen TT, Cerutti F, Berrino E, Sapino A, Bienko M, Sottile A, Ghisetti V, Crosetto N. 2021. COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance. Nat Commun 12:3903.
12. Fukuta M, Mao ZQ, Morita K, Moi ML. 2021. Stability and infectivity of SARS-CoV-2 and viral RNA in water. Front Microbiol 12:667956.
13. Yadav R, Chaudhary JK, Jain N, Chaudhary PK, Khanra S, Dhamija P, Sharma A, Kumar A, Handu S. 2021. Role of structural and nonstructural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells 10:821.
14. Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ. 2020. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588:327–330.
15. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Peacock SJ, Robertson DL, COVID-19 Genomics U.K. (COG-UK) Consortium. 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19:409–424.
16. Higdon, M. M., Wahl, B., Jones, C. B., Rosen, J. G., Truelove, S. A., Baidya, A., Nande, A. A., ShamaeiZadeh, P. A., Walter, K. K., Feikin, D. R., Patel, M. K., Deloria Knoll, M., & Hill, A. L. (2022). A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. In Open Forum Infectious Diseases (Vol. 9, Issue 6). Oxford University Press (OUP). https://doi.org/10.1093/ofid/ofac138
17. Neuman BW, Brashear WA, Brun M, Chaki SP, Fischer RSB, Guidry SJ, Hill JE, Hillhouse AE, Johnson CD, Kahl-McDonagh MM, Metz RP, Rice-Ficht AC, Shuford JA, Skaggs TA, Stull MA, Threadgill DW, Akpalu Y, Zuelke K.
18. Kliker L, Zuckerman N, Atari N, et al. Covid-19 vaccination and Ba.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and Ba.5 Omicron variants, Israel, March to june 2022. Eurosurveillance. 2022;27(30). doi:10.2807/1560-7917.es.2022.27.30.2200559
19. Costa Clemens SA;Weckx L;Clemens R;Almeida Mendes AV;Ramos Souza A;Silveira MBV;da Guarda SNF;de Nobrega MM;de Moraes Pinto MI;Gonzalez IGS;Salvador N;Franco MM;de Avila Mendonça RN;Queiroz Oliveira IS;de Freitas Souza BS;Fraga M;Aley P;Bibi S;Cantrell L; Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of Coronavac COVID-19 vaccine in Brazil (RHH-001): A phase 4, non-inferiority, single blind, Randomised Study. Lancet (London, England). https://pubmed.ncbi.nlm.nih.gov/35074136/. Accessed February 13, 2023.